IMPROVED AORTOCORONARY BYPASS PATENCY BY LOW-DOSE ASPIRIN (100 mg DAILY): Effects on Platelet Aggregation and Thromboxane Formation

doi:10.1016/S0140-6736(84)92446-2

The Lancet

Volume 323, Issue 8389, 9 June 1984, Pages 1261-1264

https://doi.org/10.1016/S0140-6736(84)92446-2 Get rights and content

Abstract

Prevention of aortocoronary bypass occlusion by aspirin (ASA, 1 × 100 mg per day) was studied in a prospective double-blind trial of 83 patients. 60 (72%) were randomly allocated to ASA or placebo starting 24 h after operation. 90% of grafts in the ASA group and 68% in the placebo group were patent at four months. At least one anastomosis was occluded in 62% of the patients on placebo and in 27% of those on aspirin. Ventricular arrhythmias increased after surgery in more patients on placebo (12/18) than in patients on ASA (5/17). Platelet thromboxane formation on collagen tested before operation was significantly higher in patients in whom bypass occlusion developed (occlusion: 40±19, no occlusion: 25±13 ng/ml). A 100 mg dose of ASA per day effectively blocked platelet thromboxane formation and thromboxane-supported aggregation on collagen and was safe in the postoperative phase. No side effects were reported throughout the trial. The reduced toxicity with full efficacy favours a low and infrequent dosage of aspirin.

References (35)

J. O'Grady et al.
Aspirin: a paradoxical effect on bleeding time
Lancet
(1978)
M. Livio et al.
Aspirin, thromboxane, and prostacyclin in rats: a dilemma resolved
Lancet
(1978)
G. Masotti et al.
Differential inhibition of prostacyclin production and platelet aggregation by aspirin
Lancet
(1979)
Gm Lawrie et al.
Vein graft patency and intimal proliferation after aortocoronary bypass: early and long-term angiopathologic correlations
Am J Cardiol
(1976)
Mp Metke et al.
Reduction of intimal thickening in canine coronary artery bypass vein grafts with dipyridamole and aspirin
Am J Cardiol
(1979)
R. Lorenz et al.
Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man
Eur J Pharmacol
(1981)
Sp Hanley et al.
Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis
Lancet
(1981)
Rb Philp et al.
Low-dose aspirin (ASA) renders human platelets more vulnerable to inhibition of aggregation by prostacyclin (PGI2)
Prost Leukotri Med
(1983)
Hr Baur et al.
Effects of sulfinpyrazone on early graft closure after myocardial revascularisation
Am J Cardiol
(1982)
Bg Brown et al.
Improved graft patency with antiplatelet drugs in patients treated for one year following coronary bypass surgery
Am J Cardiol
(1981)

Pr Kowey et al.

Influence of intracoronary platelet aggregation on ventricular electrical properties during partial coronary artery stenosis

Am J Cardiol

(1983)

M. Hamberg et al.

A new group of biologically active compounds derived from prostaglandin endoperoxides

Proc Natl Acad Sci USA

(1975)

S. Moncada et al.

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

Nature

(1976)

Hr Harter et al.

Prevention of thrombosis in patients on hemodialysis by low-dose aspirin

N Engl J Med

(1979)

Sh Rahimtoola

Coronary bypass surgery for chronic angina-1981. A perspective

Circulation

(1982)

P. Steele et al.

Correlation of platelet survival time with occlusion of saphenous vein aortocoronary bypass grafts

Circulation

(1976)

Ga Pantely et al.

Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass

N Engl J Med

(1979)

Cited by (237)

2023 AHA/ACC Clinical Performance and Quality Measures for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures
2023, Journal of the American College of Cardiology
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2022, Journal of the American College of Cardiology
The guideline for coronary artery revascularization replaces the 2011 coronary artery bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines, providing a patient-centric approach to guide clinicians in the treatment of patients with significant coronary artery disease undergoing coronary revascularization as well as the supporting documentation to encourage their use.
A comprehensive literature search was conducted from May 2019 to September 2019, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, CINHL Complete, and other relevant databases. Additional relevant studies, published through May 2021, were also considered.
Coronary artery disease remains a leading cause of morbidity and mortality globally. Coronary revascularization is an important therapeutic option when managing patients with coronary artery disease. The 2021 coronary artery revascularization guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with coronary artery disease who are being considered for coronary revascularization, with the intent to improve quality of care and align with patients’ interests.
Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid
2017, Thrombosis Research
Current guidelines recommend acetylsalicylic acid (ASA) treatment after coronary artery bypass grafting (CABG) to reduce thrombotic vein graft occlusion. The optimal dosage of ASA is not known.
Forty-two patients undergoing elective CABG were randomized to receive either ASA 75 mg or 160 mg once daily (OD) or 75 mg twice daily (BID) after the operation. Platelet function testing was performed before, and one and three months after the operation.
White blood cell counts increased during the initial postoperative days whereas platelet counts were initially slightly reduced after the operation but increased after one month without any major changes of mean platelet volumes. Serum thromboxane B₂ was more effectively suppressed at one and three months after the operation with ASA 75 mg BID or 160 mg OD than with 75 mg OD (p < 0.001). ASA 75 mg BID and 160 mg OD were equally effective. Adenosine diphosphate stimulated platelet aggregation in whole blood (Multiplate®) was increased one and three months after the operation, and this was counteracted by ASA 75 mg BID but not by 75 or 160 mg OD. Arachidonic acid-induced aggregation was more effectively inhibited by 75 mg BID or 160 mg OD compared to 75 mg OD at three months.
Less effective inhibition of platelet activation was obtained with ASA 75 mg OD than with ASA 160 mg OD or 75 mg BID up to three months after CABG. Especially the latter dose is of interest for further studies of efficacy and clinical outcomes after CABG.
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2016, Journal of Thoracic and Cardiovascular Surgery
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2016, Journal of the American College of Cardiology
Antithrombotic strategies for preventing graft failure in coronary artery bypass graft
2024, Journal of Thrombosis and Thrombolysis

View all citing articles on Scopus

View full text

IMPROVED AORTOCORONARY BYPASS PATENCY BY LOW-DOSE ASPIRIN (100 mg DAILY): Effects on Platelet Aggregation and Thromboxane Formation

Abstract

Lancet

Lancet

Lancet

Am J Cardiol

Am J Cardiol

Eur J Pharmacol

Lancet

Prost Leukotri Med

Am J Cardiol

Am J Cardiol

Am J Cardiol

A new group of biologically active compounds derived from prostaglandin endoperoxides

Proc Natl Acad Sci USA

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

Nature

Prevention of thrombosis in patients on hemodialysis by low-dose aspirin

N Engl J Med

Coronary bypass surgery for chronic angina-1981. A perspective

Circulation

Correlation of platelet survival time with occlusion of saphenous vein aortocoronary bypass grafts

Circulation

Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass

N Engl J Med